Q32 Bio Inc. Fundamental Analysis
Q32 Bio Inc. (QTTB) shows moderate financial fundamentals with a PE ratio of 4.21, profit margin of 61.86%, and ROE of 2.31%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 73.9/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze QTTB's fundamental strength across five key dimensions:
Efficiency Score
ExcellentQTTB demonstrates superior asset utilization.
Valuation Score
ExcellentQTTB trades at attractive valuation levels.
Growth Score
ModerateQTTB shows steady but slowing expansion.
Financial Health Score
ExcellentQTTB maintains a strong and stable balance sheet.
Profitability Score
ModerateQTTB maintains healthy but balanced margins.
Key Financial Metrics
Is QTTB Expensive or Cheap?
P/E Ratio
QTTB trades at 4.21 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, QTTB's PEG of 0.01 indicates potential undervaluation.
Price to Book
The market values Q32 Bio Inc. at 3.43 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 8.18 times EBITDA. This is generally considered low.
How Well Does QTTB Make Money?
Net Profit Margin
For every $100 in sales, Q32 Bio Inc. keeps $61.86 as profit after all expenses.
Operating Margin
Core operations generate 39.84 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $2.31 in profit for every $100 of shareholder equity.
ROA
Q32 Bio Inc. generates $52.21 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Q32 Bio Inc. generates limited operating cash flow of $-24.84M, signaling weaker underlying cash strength.
Free Cash Flow
Q32 Bio Inc. generates weak or negative free cash flow of $-24.84M, restricting financial flexibility.
FCF Per Share
Each share generates $-1.94 in free cash annually.
FCF Yield
QTTB converts -18.85% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
4.21
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.01
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.43
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.68
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.29
vs 25 benchmark
Current Ratio
Current assets to current liabilities
5.36
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
2.31
vs 25 benchmark
ROA
Return on assets percentage
0.52
vs 25 benchmark
ROCE
Return on capital employed
0.40
vs 25 benchmark
How QTTB Stacks Against Its Sector Peers
| Metric | QTTB Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 4.21 | 29.54 | Better (Cheaper) |
| ROE | 230.68% | 418.00% | Weak |
| Net Margin | 61.86% | -11410.00% (disorted) | Strong |
| Debt/Equity | 0.29 | 0.77 | Strong (Low Leverage) |
| Current Ratio | 5.36 | 5.08 | Strong Liquidity |
| ROA | 52.21% | -177.00% (disorted) | Strong |
QTTB outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Q32 Bio Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation